Product image of Letrozole Sanoswiss (Letrozole) supplied by GNH India

Letrozole Sanoswiss

Active Ingredient:
Letrozole
Origin:
EU

Letrozole Sanoswiss (Letrozole)

Letrozole, the active ingredient in Letrozole Sanoswiss, is an aromatase inhibitor presented as an oral tablet for oral use. It treats hormone‑receptor‑positive breast cancer in postmenopausal women.

GNH India supplies Letrozole Sanoswiss as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Manufacturer / TM Owner

Uab Sanoswiss

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer.

  • Hormone‑receptor‑positive early‑stage breast cancer (postmenopausal): reduces risk of recurrence by lowering estrogen production.
  • Hormone‑receptor‑positive advanced/metastatic breast cancer (postmenopausal): slows disease progression through estrogen suppression.
  • Adjuvant therapy for postmenopausal breast cancer: supports long‑term disease‑free survival after surgery.

How It Works

  • Letrozole selectively and non‑steroidally inhibits the aromatase enzyme, which converts androstenedione and testosterone to estrone and estradiol. By blocking this conversion, systemic estrogen levels decline, depriving estrogen‑dependent tumor cells of a growth stimulus and thereby inhibiting proliferation of hormone‑sensitive breast cancer.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Hot flashes: transient episodes of increased skin temperature.
  • Joint and muscle pain: aching discomfort in limbs.
  • Fatigue: generalized lack of energy.
  • Nausea: mild to moderate upset stomach.
  • Headache: occasional throbbing pain.
  • Elevated cholesterol: modest increase in lipid levels.

Serious or Rare Side Effects

  • Severe liver injury: jaundice, elevated transaminases.
  • Osteoporotic fractures: increased risk of bone breakage.
  • Deep vein thrombosis or pulmonary embolism: clot formation in veins.
  • Cardiovascular events: myocardial infarction or stroke.
  • Severe allergic reactions: rash, swelling, anaphylaxis.
  • Hyperglycemia: significant rise in blood glucose levels.

Precautions & Warnings

Patients should be monitored for safety considerations before and during therapy.

  • Monitor bone health: assess bone mineral density periodically.
  • Check liver function: perform baseline and periodic hepatic enzyme tests.
  • Assess cardiovascular risk: monitor blood pressure, lipid profile, and signs of thrombosis.
  • Avoid use in premenopausal women: not indicated for this population.
  • Pregnancy and lactation: contraindicated unless benefits outweigh risks.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Letrozole may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly decrease letrozole plasma levels.
  • Tamoxifen: antagonistic hormonal effects may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): may increase INR and bleeding risk.
  • Selective serotonin reuptake inhibitors (e.g., fluoxetine): potential alteration of letrozole metabolism.
  • Statins (e.g., simvastatin): possible changes in lipid‑lowering efficacy.
  • Hormonal contraceptives: reduced effectiveness due to estrogen suppression.
  • Thyroid hormone replacement (levothyroxine): may require dose adjustment.

Frequently Asked Questions

Letrozole Sanoswiss contains the active ingredient letrozole, an aromatase inhibitor indicated for the treatment of hormone‑receptor‑positive breast cancer in postmenopausal women, both in early‑stage (adjuvant) and advanced/metastatic settings.

Letrozole blocks the aromatase enzyme, preventing the conversion of androgens to estrogens. This reduction in circulating estrogen deprives estrogen‑dependent tumor cells of a growth signal, thereby inhibiting cancer cell proliferation.

The specific dose and dosing schedule are determined by the prescribing physician based on the patient’s clinical condition, treatment goals, and individual factors. Patients should follow the prescriber’s instructions precisely.

Letrozole is contraindicated in pregnancy because it can harm the developing fetus. It is also not recommended during breastfeeding as it may pass into breast milk. Women of child‑bearing potential should use effective contraception while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Letrozole, as a non‑steroidal aromatase inhibitor, offers more complete estrogen suppression than selective estrogen receptor modulators such as tamoxifen. Clinical studies have shown improved disease‑free survival in postmenopausal women, though the safety profile and side‑effect spectrum differ and must be considered.

Letrozole Sanoswiss should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain potency.

The medication is taken orally, usually as a tablet, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare provider.

Serious risks include severe liver injury, osteoporotic fractures, deep‑vein thrombosis or pulmonary embolism, cardiovascular events such as myocardial infarction or stroke, and rare allergic reactions. Patients should be monitored regularly for these complications.

Letrozole is not indicated for premenopausal women, pregnant or nursing individuals, and patients with known hypersensitivity to letrozole or any excipients. It should also be avoided in patients with severe hepatic impairment unless specifically directed by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT